Harnessing NAD+ Metabolism as Therapy for Cardiometabolic Diseases

Curr Heart Fail Rep. 2022 Aug;19(4):157-169. doi: 10.1007/s11897-022-00550-5. Epub 2022 May 13.


Purpose of the review: This review summarizes current understanding on the roles of nicotinamide adenine dinucleotide (NAD+) metabolism in the pathogeneses and treatment development of metabolic and cardiac diseases.

Recent findings: NAD+ was identified as a redox cofactor in metabolism and a co-substrate for a wide range of NAD+-dependent enzymes. NAD+ redox imbalance and depletion are associated with many pathologies where metabolism plays a key role, for example cardiometabolic diseases. This review is to delineate the current knowledge about harnessing NAD+ metabolism as potential therapy for cardiometabolic diseases. The review has summarized how NAD+ redox imbalance and depletion contribute to the pathogeneses of cardiometabolic diseases. Therapeutic evidence involving activation of NAD+ synthesis in pre-clinical and clinical studies was discussed. While activation of NAD+ synthesis shows great promise for therapy, the field of NAD+ metabolism is rapidly evolving. Therefore, it is expected that new mechanisms will be discovered as therapeutic targets for cardiometabolic diseases.

Keywords: Cardiometabolic diseases; Heart failure; NAD+ metabolism; Redox balance.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Heart Diseases*
  • Heart Failure*
  • Humans
  • NAD / metabolism
  • Oxidation-Reduction


  • NAD